Wednesday, March 30, 2022

Ayala Pharmaceuticals (AYLA)
Ayala Reports FY21 and Reiterates Trial Data Expectations

Ayala Pharmaceuticals Inc clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. The company’s current portfolio of product candidates, AL101 and AL102, targets the aberrant activation of the Notch pathway with gamma secretase inhibitors. Its product candidate, AL101, is being developed as a potent, selective, injectable small molecule gamma secretase inhibitor, or GSI. It is also developing AL101 for the treatment of T-ALL, an aggressive, rare form of T-cell specific leukemia.

Robert LeBoyer, Vice President, Research Analyst, Life Sciences, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Ayala Reported FY2021 Within Expectations Ayala Reported FY2021 loss of $40.3 million or $(2.80) per share.  This compares with our estimate of a loss of $40.9 million or $(3.00) per share, as both R&D and General Expenses were slightly below our estimates. Cash balance on December 31 was $37.3 million.

One New Study Testing AL101 Is Underway, Another To Begin In 2H22.  The “Window of Opportunity” study testing AL101 in ACC (adenoid cystic carcinoma) has begun treating patients prior to surgery and radiation therapy. This is intended to reduce recurrence rates and improve long-term survival, as well as to define the mechanism and effects of AL101 on cancer. Separately, the Phase 2 trial in T-ALL …

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.